Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cancer drug injected directly into tumors in early human trial

NCT ID NCT03871348

Terminated Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

Summary

This was an early-stage study to test the safety and find the right dose of a new cancer drug called SAR441000. The drug was injected directly into tumors, both by itself and combined with an existing immunotherapy (cemiplimab), in 77 adults with advanced solid cancers that had spread and had no other standard treatment options. The main goals were to see how much of the drug patients could tolerate and to check for early signs that it might help shrink tumors.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC NEOPLASM are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Cleveland Clinic - Cleveland- Site Number : 8400007

    Cleveland, Ohio, 44195, United States

  • Dana-Farber Cancer Institute- Site Number : 8400003

    Boston, Massachusetts, 02215, United States

  • Investigational Site Number : 0560001

    Brussels, 1200, Belgium

  • Investigational Site Number : 0560002

    Leuven, 3000, Belgium

  • Investigational Site Number : 0560003

    Ghent, 9000, Belgium

  • Investigational Site Number : 2500001

    Villejuif, 94805, France

  • Investigational Site Number : 2500002

    Paris, 75010, France

  • Investigational Site Number : 2500004

    Marseille, 13885, France

  • Investigational Site Number : 2760001

    Mainz, 55131, Germany

  • Investigational Site Number : 2760003

    Mannheim, 68167, Germany

  • Investigational Site Number : 2760004

    Heidelberg, 69120, Germany

  • Investigational Site Number : 2760005

    Hamburg, 20246, Germany

  • Investigational Site Number : 2760006

    Tübingen, 72076, Germany

  • Investigational Site Number : 5280001

    Rotterdam, 3015 CE, Netherlands

  • Investigational Site Number : 5280002

    Nijmegen, 6525 GA, Netherlands

  • Investigational Site Number : 7240001

    Pamplona, Navarre, 31008, Spain

  • Investigational Site Number : 7240002

    Valencia, 46014, Spain

  • Investigational Site Number : 7240004

    Barcelona, Catalunya [Cataluña], 08036, Spain

  • The University of Texas MD Anderson Cancer Center- Site Number : 8400002

    Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.

METASTATIC NEOPLASM